Coromandel International Limited (COROMANDEL) Fair Value & Analysis
Basic Materials · IN · Market cap ₹529B
Analysis
Coromandel International Limited (COROMANDEL) currently trades at ₹1,993, while our model-based Fair Value estimate is ₹1,129 — implying the stock looks roughly 43.3% overvalued today. We read business quality at 93/100 (high quality), in the Basic Materials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Coromandel International Limited provides agriculture solutions in India and internationally. It operates through the Nutrient and Other Allied Business, and Crop Protection segments. The company offers fertilizers, including GroPlus Pro Mg and Gromor Urea Super Phosphate; bio-products comprising MycoRitz and Grovibe; specialty nutrients, such as Pixibud, Pixigrow, Nano Urea, Areca Shakti, and Coffee Bliss; and crop protection products that include Caveco, Marvex, Prachand, Benofit, Rukawat X, Myconil, Eezykil Ultra, Cortus, Victini Z, and Toscee. It also provides value-added services, including drone spraying, soil testing, crop diagnostics, and weather insights, as well as e-commerce platform for advisory and ordering. The company was formerly known as Coromandel Fertilisers Ltd and changed its name to Coromandel International Limited in September 2009. Coromandel International Limited was incorporated in 1961 and is based in Chennai, India. Coromandel International Limited operat…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.